INTRODUCTION: During the past few years, medical-economic evaluation of lung cancers (LCs) has become unavoidable. Total management costs have been rising constantly, with values almost doubling every 10 years. The financial impact will be even greater with the new molecules now marketed. The methodology for these studies conforms with international recommendations but must be adapted to the new stakes of LC management. Areas covered: This review provides an overview of the available literature concerning the economics of treating non-small-cell lung cancer (NSCLC). We first address the global costs of LCs. Detailed analyses were then computed for the different LC stages: localized, locally advanced and metastatic. For metastatic NSCLC, subsections are devoted to targeted therapies and immunotherapies. Expert commentary: Drug costs are one of the major challenges of LC management. The multiplication of medical-economic analyses will assure better access to the marketing of these new and expensive therapeutic agents, but also to the selection of the best management strategy for these cancers.
Review of economic analyses of treatment for non-small-cell lung cancer (NSCLC).
Expert Rev Pharmacoecon Outcomes Res. 2018;18(5):519-528.
MeSH terms: Carcinoma, Non-Small-Cell Lung; Drug Costs; Humans; Immunotherapy; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging